Evaluating Biologic Options and Monitoring Response in CSU

Segment summary: This episode titled “Evaluating Biologic Options and Monitoring Response in CSU,” focuses on outcomes data for the biologic targeting the IL-4 receptor pathway, dupilumab. Over a 24-week horizon, overall efficacy is broadly comparable to remibrutinib, but the path to improvement looks different: the BTK inhibitor produces a sharp separation from placebo within about four weeks, while the biologic shows a more gradual, steady improvement that takes closer to four months to reach a similar plateau.

Dupilumab’s decade-long track record is highlighted, with millions of patients treated across other approved indications, and it appears even better tolerated in urticaria than in atopic dermatitis, where conjunctivitis is a known side effect that does not appear in CSU patients. As with the other advanced options, about two-thirds of patients do well while roughly one-third require a change in therapy. Patient preference ultimately hinges on desired speed of onset, route of administration, comorbid atopic conditions, and, for younger patients, age-based approval differences, noting dupilumab’s recent approval down to age two, though both speakers acknowledge seeing few or no pediatric CSU cases in their own practices.

On monitoring, a consistent 12-week follow-up across all three advanced therapy classes is used to decide whether to continue or switch, since waiting longer only prolongs patient suffering if a drug is not working. It is also routine to confirm that patients have not quietly discontinued their background antihistamine, which can mimic treatment failure. Finally, with three effective advanced options now available, cyclosporine use has become rare, with only one current patient remaining on it as an adjunct after a partial response to biologic therapy. In the next episode, “Building Therapeutic Alliance and Addressing Access Barriers in CSU,” the panel shares strategies for educating patients about the autoimmune and dietary aspects of CSU and discusses real-world coverage and access challenges.